PMID- 29854250
OWN - NLM
STAT- MEDLINE
DCOM- 20190226
LR  - 20190226
IS  - 1942-597X (Electronic)
IS  - 1559-4076 (Linking)
VI  - 2017
DP  - 2017
TI  - Towards precision informatics of pharmacovigilance: OAE-CTCAE mapping and 
      OAE-based representation and analysis of adverse events in patients treated with 
      cancer drugs.
PG  - 1793-1801
AB  - A critical issue in the usage of cancer drugs is its association with various 
      adverse events (AEs) in some, but not all, patients. The National Cancer 
      Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) is a 
      controlled terminology for AE classification and analysis in cancer clinical 
      trials. The Ontology of Adverse Events (OAE) is a community-based ontology in the 
      domain of AEs. In this study, OAE was first updated by including AE severity 
      grading and OAE-CTCAE mapping. An OAE subset containing CTCAE-related terms and 
      their associated OAE terms was generated to facilitate term usage. A use case 
      study based on a published cancer drug clinical trial demonstrates that OAE 
      provides better hierarchical representation, includes semantic relations, and 
      supports automated reasoning. Demonstrated with a single patient analysis, the 
      OAE framework supports precision informatics for representing AEs and related 
      genetic and clinical conditions in individual patients treated with cancer drugs.
FAU - Wong, Mei U
AU  - Wong MU
AD  - University of Michigan, Ann Arbor, MI, USA.
FAU - Racz, Rebecca
AU  - Racz R
AD  - University of Michigan, Ann Arbor, MI, USA.
AD  - Division of Applied Regulatory Science, Office of Clinical Pharmacology, Food and 
      Drug Administration, Silver Spring, MD, USA.
FAU - Ong, Edison
AU  - Ong E
AD  - University of Michigan, Ann Arbor, MI, USA.
FAU - He, Yongqun
AU  - He Y
AD  - University of Michigan, Ann Arbor, MI, USA.
LA  - eng
PT  - Journal Article
DEP - 20180416
PL  - United States
TA  - AMIA Annu Symp Proc
JT  - AMIA ... Annual Symposium proceedings. AMIA Symposium
JID - 101209213
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - *Biological Ontologies
MH  - Drug-Related Side Effects and Adverse Reactions/*classification
MH  - Humans
MH  - Medical Informatics
MH  - Neoplasms/*drug therapy
MH  - *Pharmacovigilance
MH  - Semantics
MH  - Severity of Illness Index
PMC - PMC5977606
EDAT- 2018/06/02 06:00
MHDA- 2019/02/27 06:00
PMCR- 2018/04/16
CRDT- 2018/06/02 06:00
PHST- 2018/06/02 06:00 [entrez]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2019/02/27 06:00 [medline]
PHST- 2018/04/16 00:00 [pmc-release]
AID - 2731377 [pii]
PST - epublish
SO  - AMIA Annu Symp Proc. 2018 Apr 16;2017:1793-1801. eCollection 2017.